Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GDC-0810 (Brilanestrant) Alone or in Combination in Advanced ER+ Breast Cancer
NCT01823835Phase 2Terminated
- Sponsor
- Genentech
- Start
- Dec 2014
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of brilanestrant in breast cancer, sponsored by Genentech. Started Dec 2014; status: terminated.
02
Drugs
brilanestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01823835.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01823835.